Hanne Kuitunen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hanne Kuitunen has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Outi Kuittinen
Faculty of Health Medicine, Institute of Clinical Medicine University of Eastern Finland Kuopio Finland
9 shared publications Esa Jantunen
Institute of Clinical Medicine, University of Eastern Finland and Department of Medicine, North Carelia Central Hospital, Joensuu, Finland
5 shared publications- Hanna-Riikka Teppo
Cancer Research and Translational Medicine Research Unit, University of Oulu, 90014 Oulu, Finland
4 shared publications - Aino Rajamäki
Department of Oncology Hospital Nova of Central Finland Jyväskylä Finland
3 shared publications - Aino Rönkä
Faculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland Kuopio Finland
3 shared publications - Annamari Ranki
Department of Skin and Allergic Diseases, University of Helsinki, Helsinki University Central Hospital, P.O. Box 160, 00029 HUS Helsinki, Finland
3 shared publications
Latest Publications
- Open Access
- 10 May 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (5) , e71920
Socioeconomic Status and Access to Treatment in Diffuse Large B‐Cell Lymphoma
Background and Purpose: Large B‐cell lymphoma (LBCL) is the most common lymphoma subtype, with diffuse LBCL (DLBCL) accounting for 30%–40% of new lymphoma cases. The International Prognostic Index (IPI) is widely used for prognostic assessment in DLBCL. Clinical features associated with a poorer prognosis, such as advanced disease stage, could be a consequence of delayed diagnosis, which in turn may be influenced by a patient's socioeconomic status. While healthcare in Finland aims to ensure equal access to timely and high‐quality treatment for all, disparities still exist. In this study we evaluated the impact of patients' socioeconomic status on their access to diagnostic procedures. Patient/Material and Methods: Patient data was prospectively collected from seven hospitals between October 2014 and March 2020 in Finland. A total of 160 patients provided information regarding their diagnostic pathway and socioeconomic status via questionnaire. The data was combined with clinical data from patient records. Results: The symptoms to treatment interval (STI) varied between age groups ( p = 0.019), marital status groups ( p = 0.023), and healthcare providers. In addition, age, income level, and occupational status (all p < 0.001) influenced which healthcare provider patients used as their first place of contact. Interpretation: In this prospective study, we analyzed the impact of patients' socioeconomic status on treatment delays within the treatment pathway. Socioeconomic status was found to have a significant effect on these delays. The delays varied not only between different socioeconomic groups but also across different healthcare providers.
- 10 May 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (5) , e71920
Open AccessSocioeconomic Status and Access to Treatment in Diffuse Large B‐Cell Lymphoma
Background and Purpose: Large B‐cell lymphoma (LBCL) is the most common lymphoma subtype, with diffuse LBCL (DLBCL) accounting for 30%–40% of new lymphoma cases. The International Prognostic Index (IPI) is widely used for prognostic assessment in DLBCL. Clinical features associated with a poorer prognosis, such as advanced disease stage, could be a consequence of delayed diagnosis, which in turn may be influenced by a patient's socioeconomic status. While healthcare in Finland aims to ensure equal access to timely and high‐quality treatment for all, disparities still exist. In this study we evaluated the impact of patients' socioeconomic status on their access to diagnostic procedures. Patient/Material and Methods: Patient data was prospectively collected from seven hospitals between October 2014 and March 2020 in Finland. A total of 160 patients provided information regarding their diagnostic pathway and socioeconomic status via questionnaire. The data was combined with clinical data from patient records. Results: The symptoms to treatment interval (STI) varied between age groups ( p = 0.019), marital status groups ( p = 0.023), and healthcare providers. In addition, age, income level, and occupational status (all p < 0.001) influenced which healthcare provider patients used as their first place of contact. Interpretation: In this prospective study, we analyzed the impact of patients' socioeconomic status on treatment delays within the treatment pathway. Socioeconomic status was found to have a significant effect on these delays. The delays varied not only between different socioeconomic groups but also across different healthcare providers.
- 6 September 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (3) , 700-703.e5
Tumor RNA Sequencing Identifies a Group of Patients with Mycosis Fungoides with Failure of Skin-Directed Therapies
- 6 September 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (3) , 700-703.e5
Tumor RNA Sequencing Identifies a Group of Patients with Mycosis Fungoides with Failure of Skin-Directed Therapies
- Open Access
Predictive Factors for Early Immune Recovery in NHL Patients after Autologous Transplantation: A Multicenter Prospective Study
Early lymphocyte recovery as manifested by an absolute lymphocyte count at d+15 (ALC-15) ≥ 0.5 × 109/L after autologous hematopoietic stem cell transplantation (AHCT) has been associated with a better outcome. This prospective multicenter study aimed to clarify factors associated with ALC-15 ≥ 0.5 × 109/L after AHCT among 178 patients with non-Hodgkin lymphoma. The mobilization capacity, as manifested by peak blood CD34+ cell numbers > 45 × 106/L correlated with higher ALC-15 levels (p = 0.020). In addition, the amount of CD3+CD4+ T cells > 31.8 × 106/kg in the infused graft predicted ALC-15 ≥ 0.5 × 109/L (p < 0.001). Also, the number of infused graft CD3+CD8+ T cells > 28.8 × 106/kg (p = 0.017) and NK cells > 4.4 × 106/kg was linked with higher ALC-15 (p < 0.001). The two-year progression-free survival after AHCT was significantly better in patients with ALC-15 ≥ 0.5 × 109/L (74 vs. 57%, p = 0.027). The five-year OS in patients with higher ALC-15 was 78% vs. 60% in those with lower ALC-15 (p = 0.136). To conclude, the mobilization capacity of CD34+ cells and detailed measures of graft cellular content mark prognostic tools that predict ALC-15 ≥ 0.5 × 109/L, which is associated with a better outcome in NHL patients after AHCT.
Open AccessPredictive Factors for Early Immune Recovery in NHL Patients after Autologous Transplantation: A Multicenter Prospective Study
Early lymphocyte recovery as manifested by an absolute lymphocyte count at d+15 (ALC-15) ≥ 0.5 × 109/L after autologous hematopoietic stem cell transplantation (AHCT) has been associated with a better outcome. This prospective multicenter study aimed to clarify factors associated with ALC-15 ≥ 0.5 × 109/L after AHCT among 178 patients with non-Hodgkin lymphoma. The mobilization capacity, as manifested by peak blood CD34+ cell numbers > 45 × 106/L correlated with higher ALC-15 levels (p = 0.020). In addition, the amount of CD3+CD4+ T cells > 31.8 × 106/kg in the infused graft predicted ALC-15 ≥ 0.5 × 109/L (p < 0.001). Also, the number of infused graft CD3+CD8+ T cells > 28.8 × 106/kg (p = 0.017) and NK cells > 4.4 × 106/kg was linked with higher ALC-15 (p < 0.001). The two-year progression-free survival after AHCT was significantly better in patients with ALC-15 ≥ 0.5 × 109/L (74 vs. 57%, p = 0.027). The five-year OS in patients with higher ALC-15 was 78% vs. 60% in those with lower ALC-15 (p = 0.136). To conclude, the mobilization capacity of CD34+ cells and detailed measures of graft cellular content mark prognostic tools that predict ALC-15 ≥ 0.5 × 109/L, which is associated with a better outcome in NHL patients after AHCT.
- Open Access
- 7 September 2023
- Published by Wiley in HemaSphere
- Vol. 7 (10) , e954
Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria
- 7 September 2023
- Published by Wiley in HemaSphere
- Vol. 7 (10) , e954
Open AccessReal-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria
- Open Access
- 31 July 2023
- Published by Wiley in British Journal of Haematology
Rapid diagnosis and initiation of treatment has a crucial role in the prognosis of primary central nervous system lymphoma
- 31 July 2023
- Published by Wiley in British Journal of Haematology
Open AccessRapid diagnosis and initiation of treatment has a crucial role in the prognosis of primary central nervous system lymphoma
- Open Access
The Transcription Factor Twist1 Has a Significant Role in Mycosis Fungoides (MF) Cell Biology: An RNA Sequencing Study of 40 MF Cases
The purpose of this RNA sequencing study was to investigate the biological mechanism underlying how the transcription factors (TFs) Twist1 and Zeb1 influence the prognosis of mycosis fungoides (MF). We used laser-captured microdissection to dissect malignant T-cells obtained from 40 skin biopsies from 40 MF patients with stage I–IV disease. Immunohistochemistry (IHC) was used to determinate the protein expression levels of Twist1 and Zeb1. Based on RNA sequencing, principal component analysis (PCA), differential expression (DE) analysis, ingenuity pathway analysis (IPA), and hub gene analysis were performed between the high and low Twist1 IHC expression cases. The DNA from 28 samples was used to analyze the TWIST1 promoter methylation level. In the PCA, Twist1 IHC expression seemed to classify cases into different groups. The DE analysis yielded 321 significant genes. In the IPA, 228 significant upstream regulators and 177 significant master regulators/causal networks were identified. In the hub gene analysis, 28 hub genes were found. The methylation level of TWIST1 promoter regions did not correlate with Twist1 protein expression. Zeb1 protein expression did not show any major correlation with global RNA expression in the PCA. Many of the observed genes and pathways associated with high Twist1 expression are known to be involved in immunoregulation, lymphocyte differentiation, and aggressive tumor biology. In conclusion, Twist1 might be an important regulator in the disease progression of MF.
Open AccessThe Transcription Factor Twist1 Has a Significant Role in Mycosis Fungoides (MF) Cell Biology: An RNA Sequencing Study of 40 MF Cases
The purpose of this RNA sequencing study was to investigate the biological mechanism underlying how the transcription factors (TFs) Twist1 and Zeb1 influence the prognosis of mycosis fungoides (MF). We used laser-captured microdissection to dissect malignant T-cells obtained from 40 skin biopsies from 40 MF patients with stage I–IV disease. Immunohistochemistry (IHC) was used to determinate the protein expression levels of Twist1 and Zeb1. Based on RNA sequencing, principal component analysis (PCA), differential expression (DE) analysis, ingenuity pathway analysis (IPA), and hub gene analysis were performed between the high and low Twist1 IHC expression cases. The DNA from 28 samples was used to analyze the TWIST1 promoter methylation level. In the PCA, Twist1 IHC expression seemed to classify cases into different groups. The DE analysis yielded 321 significant genes. In the IPA, 228 significant upstream regulators and 177 significant master regulators/causal networks were identified. In the hub gene analysis, 28 hub genes were found. The methylation level of TWIST1 promoter regions did not correlate with Twist1 protein expression. Zeb1 protein expression did not show any major correlation with global RNA expression in the PCA. Many of the observed genes and pathways associated with high Twist1 expression are known to be involved in immunoregulation, lymphocyte differentiation, and aggressive tumor biology. In conclusion, Twist1 might be an important regulator in the disease progression of MF.
- Open Access
- 13 December 2022
- Published by Wiley in British Journal of Haematology
- Vol. 201 (1) , 64-74
Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020
Summary: Mantle cell lymphoma (MCL) is a rare peripheral B‐cell lymphoma characterised by eventual relapse and progression towards a more aggressive disease biology. With the introduction of rituximab‐ and cytarabine‐based immunochemotherapy regimens, the prognosis of the disease has changed dramatically over the last two decades. To assess the real‐world survival of patients with MCL, we used a population‐based cohort of 564 patients with MCL who were diagnosed and treated between 2000 and 2020. Patient data were collected from seven Finnish treatment centres and one Spanish treatment centre. For the entire patient population, we report a 2‐year overall survival (OS) rate of 77%, a 5‐year OS of 58%, and a 10‐year OS of 32%. The estimated median OS was 80 months after diagnosis. MCL is associated with increased mortality across the entire patient population. Additionally, we assessed the survival of patients after MCL relapse with the aim of establishing a cut‐off point of prognostic significance. Based on our statistical analysis of survival after the first relapse, disease progression within 24 months of the initial diagnosis should be considered as a strong indicator of poor prognosis.
- 13 December 2022
- Published by Wiley in British Journal of Haematology
- Vol. 201 (1) , 64-74
Open AccessSurvival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020
Summary: Mantle cell lymphoma (MCL) is a rare peripheral B‐cell lymphoma characterised by eventual relapse and progression towards a more aggressive disease biology. With the introduction of rituximab‐ and cytarabine‐based immunochemotherapy regimens, the prognosis of the disease has changed dramatically over the last two decades. To assess the real‐world survival of patients with MCL, we used a population‐based cohort of 564 patients with MCL who were diagnosed and treated between 2000 and 2020. Patient data were collected from seven Finnish treatment centres and one Spanish treatment centre. For the entire patient population, we report a 2‐year overall survival (OS) rate of 77%, a 5‐year OS of 58%, and a 10‐year OS of 32%. The estimated median OS was 80 months after diagnosis. MCL is associated with increased mortality across the entire patient population. Additionally, we assessed the survival of patients after MCL relapse with the aim of establishing a cut‐off point of prognostic significance. Based on our statistical analysis of survival after the first relapse, disease progression within 24 months of the initial diagnosis should be considered as a strong indicator of poor prognosis.
- Open Access
- 3 March 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-8
Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis
Background: We report here the first population-based incidence rates and prognosis of primary central nervous system lymphoma (PCNSL) in Finland. Methods: Finnish Cancer Registry data by histological diagnosis and tumor location (2007–2017) for cases with diffuse large B-cell lymphoma. Results: During 2007–2017, 392 new cases of PCNSL were reported (195 males, 197 females). The average age-adjusted incidence was 0.68/100,000 person-years. Incidence for males was 0.74/100,000 and for females 0.63/100,000, respectively. The incidence was highest, 2.93/100,000, among people aged 75–79 years. Concerning all cases in 2007–2017 the 2-year age-adjusted relative survival rate was 33% and the corresponding 5-year survival rate was 26%. Among patients under the age of 70, the age-adjusted 5-year relative survival rate increased from 36% in 2007–2012 to 43% for 2013–2017. Among patients aged 70+ the corresponding survival rates were poor, 7 and 9%. Conclusions: PCNSL incidence in Finland is among the highest reported in the world. The annual increase in incidence was 2.4%. The prognosis is still dismal, especially in elderly patients.
- 3 March 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-8
Open AccessPrimary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis
Background: We report here the first population-based incidence rates and prognosis of primary central nervous system lymphoma (PCNSL) in Finland. Methods: Finnish Cancer Registry data by histological diagnosis and tumor location (2007–2017) for cases with diffuse large B-cell lymphoma. Results: During 2007–2017, 392 new cases of PCNSL were reported (195 males, 197 females). The average age-adjusted incidence was 0.68/100,000 person-years. Incidence for males was 0.74/100,000 and for females 0.63/100,000, respectively. The incidence was highest, 2.93/100,000, among people aged 75–79 years. Concerning all cases in 2007–2017 the 2-year age-adjusted relative survival rate was 33% and the corresponding 5-year survival rate was 26%. Among patients under the age of 70, the age-adjusted 5-year relative survival rate increased from 36% in 2007–2012 to 43% for 2013–2017. Among patients aged 70+ the corresponding survival rates were poor, 7 and 9%. Conclusions: PCNSL incidence in Finland is among the highest reported in the world. The annual increase in incidence was 2.4%. The prognosis is still dismal, especially in elderly patients.
- Open Access
- 15 April 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (9) , 2151-2160
Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma
Although treatment for diffuse large B-cell lymphoma (DLBCL) has taken some notable steps in the 2000s, there are still subgroups of patients suffering from high mortality and relapse rates. To further improve treatment outcomes, it is essential to discover new mechanisms of chemotherapy resistance and create new treatment approaches to overcome them. In the present study, we analyzed the expression of chemokines and their ligands in systemic and testicular DLBCL. From our biopsy sample set of 21 testicular and 28 systemic lymphomas, we were able to demonstrate chemokine profile differences and identify associations with clinical risk factors. High cytoplasmic CXCL13 expression had correlations with better treatment response, lower disease-related mortality, and limited stage. This study suggests that active CXCR5/CXCL13 signaling could overtake the CXCR4/CXCL12 axis, resulting in a better prognosis.
- 15 April 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (9) , 2151-2160
Open AccessDifferent chemokine profile between systemic and testicular diffuse large B-cell lymphoma
Although treatment for diffuse large B-cell lymphoma (DLBCL) has taken some notable steps in the 2000s, there are still subgroups of patients suffering from high mortality and relapse rates. To further improve treatment outcomes, it is essential to discover new mechanisms of chemotherapy resistance and create new treatment approaches to overcome them. In the present study, we analyzed the expression of chemokines and their ligands in systemic and testicular DLBCL. From our biopsy sample set of 21 testicular and 28 systemic lymphomas, we were able to demonstrate chemokine profile differences and identify associations with clinical risk factors. High cytoplasmic CXCL13 expression had correlations with better treatment response, lower disease-related mortality, and limited stage. This study suggests that active CXCR5/CXCL13 signaling could overtake the CXCR4/CXCL12 axis, resulting in a better prognosis.